Biogen: Canada's Drug Agency Supports Public Reimbursement Of LEQEMBI

Eisai and Biogen said Canada’s Drug Agency issued a final recommendation supporting public reimbursement of LEQEMBI (lecanemab) for eligible patients with mild cognitive impairment or mild dementia due to Alzheimer’s. The decision is a positive regulatory milestone that can improve access and commercial uptake prospects in Canada.